Health & Fitness
Health and Fitness
Health and Fitness
Fri, October 1, 2010Thu, September 30, 2010Wed, September 29, 2010Tue, September 28, 2010Mon, September 27, 2010Sun, September 26, 2010Sat, September 25, 2010Fri, September 24, 2010Thu, September 23, 2010Wed, September 22, 2010Tue, September 21, 2010Mon, September 20, 2010Fri, September 17, 2010Thu, September 16, 2010Wed, September 15, 2010Tue, September 14, 2010Mon, September 13, 2010Sun, September 12, 2010Fri, September 10, 2010BioSante Pharmaceuticals, Inc. To Present at the JMP Healthcare Conference
Published in Health and Fitness on Wednesday, September 22nd 2010 at 5:05 GMT by Market Wire
LINCOLNSHIRE, Ill.--([ BUSINESS WIRE ])--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the JMP Healthcare Conference being held in the New York Palace Hotel, New York City from September 27-28, 2010.
Phillip B. Donenberg, BioSantea™s senior vice president of finance and CFO, will speak on Monday, September 27 at 1:00 pm ET. Mr. Donenberg will provide a status update on BioSantea™s lead program, LibiGel® (testosterone gel), in Phase III clinical studies for the treatment of female sexual dysfunction, as well as a general overview of BioSante.
About the JMP Healthcare Conference
JMP Securities presents its fifth annual healthcare industry conference, an institutional investor forum featuring more than 100 leading publicly traded and privately held companies in the areas of biotechnology, medical devices and healthcare services and facilities.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSantea™s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrina" (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSantea™s licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gela", a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLooka"), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: [ www.biosantepharma.com ].
